A Trial of Crizanlizumab for the Treatment of | Clinical Research Studies Listing

Recruiting

99 years or below

All

Phase 2

5 participants needed

1 Location

Brief description of study

Retinal vasculopathy with cerebral leukoencephalopathy (RVCL) is a very rare and fatal genetic condition that affects the smallest blood vessels, especially of the brain and eye. It causes damage in the brain and eye, and there is currently no treatment to reduce these areas of damage. Crizanlizumab has been shown to treat similar symptoms in other diseases, and it's hypothesized that treating RVCL patients with crizanlizumab will slow the progression of this damage.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Medical Research
Age: 99 years or below
Gender: All

Updated on 09 Apr 2021. Study ID: 844604

Find a site

Your Information has been sent successfully.

Message sent successfully.

We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.

If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.

Send a message

Enter your contact details to connect with study team

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

A Trial of Crizanlizumab for the Treatment of Retinal Vasculopathy with Cerebral Leukoencephalopathy (RVCL)

Brief description of study

Eligibility of study

Find a site